Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# Omniose

## Sitemaps

- [XML Sitemap](https://omniose.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [News](https://omniose.com/news/)
- [Omniose Awarded $3.6 Million Grant from NIH to Develop Vaccines against Klebsiella pneumoniae](https://omniose.com/blog/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae/) - Omniose Awarded $3.6 Million Grant from NIH to Develop Vaccines against Klebsiella pneumoniae October 11, 2022 Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, has been awarded a $3.6 million grant for the development of a Klebsiella pneumoniae vaccine from the National Institute of Allergy and Infectious Diseases of the U.S. National
- [Omniose Awarded NIH Grant of up to $3.0 Million to Develop Vaccines against Group B Streptococcus](https://omniose.com/blog/omniose-awarded-nih-grant-of-up-to-3-0-million-to-develop-vaccines-against-group-b-streptococcus/) - Omniose Awarded NIH Grant of up to $3.0 Million to Develop Vaccines against Group B Streptococcus September 27, 2023 Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, announced today a grant award up to $3.0 million for the development of a Group B Streptococcus (GBS) vaccine from the National Institute of Allergy
- [Omniose Announces Expanded Leadership Team to Develop Bioconjugate Vaccines against Serious Bacterial Threats](https://omniose.com/blog/omniose-announces-expanded-leadership-team-to-develop-bioconjugate-vaccines-against-serious-bacterial-threats/) - Omniose Announces Expanded Leadership Team to Develop Bioconjugate Vaccines against Serious Bacterial Threats April 19, 2022 Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, announced today the expansion of the leadership team to include Timothy Cooke, Ph.D., MBA as Chief Executive Officer and Roman Fleck. Ph.D., MBA as Chairperson. Dr. Cooke has
- [Omniose announces scientific collaboration with AstraZeneca to research vaccines for serious bacterial diseases](https://omniose.com/blog/omniose-announces-scientific-collaboration-with-astrazeneca-to-research-vaccines-for-serious-bacterial-diseases/) - Omniose announces scientific collaboration with AstraZeneca to research vaccines for serious bacterial diseases January 5, 2024 Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens Omniose, a preclinical biotechnology company, today announced an exclusive collaboration agreement with AstraZeneca to research potential vaccines

## Pages

- [Home](https://omniose.com/) - Expanding the range of bioconjugate vaccines to fight more bacterial threats Omniose is an early-stage biotechnology company developing polysaccharide conjugate vaccines against serious bacterial threats using its proprietary bioconjugation platform. We are expanding the range of bacterial targets that can be addressed with bioconjugate vaccines. Bioconjugation relies on single cells that simultaneously produce a polysaccharide
- [Technology](https://omniose.com/technology/) - Bioconjugation, an elegantly simple solution to improve conjugate vaccines Polysaccharide conjugate (glycoconjugate) vaccines have been enormously successful at reducing disease and deaths due to infections caused by the bacterial pathogens Haemophilus influenzae type B, Streptococcus pneumoniae, Neisseria meningitidis, and Salmonella typhi. These vaccines also fight antimicrobial resistance by reducing the use of antibiotics. Conventional
- [About](https://omniose.com/about/) - The Company Omniose was founded in 2016 based on the pioneering glycoconjugation discoveries of our scientific founders Mario Feldman and Christian Harding through a scientific collaboration that characterized a new class of conjugating enzymes. The research operations were established at BioGenerator Labs in St. Louis and the company was previously known as VaxNewMo. Omniose has
- [Publications](https://omniose.com/publications/) - Publications Hwang, W.; Wantuch P.L.; Bernshtein, B.; Zhiteneva, J.A.; Slater, D.M.; Vater, K.H.; Sridhar, S.; Oliver, E.; Roach, D.J.; Rao, S.R.; Turbett, S.E.; Knoot, C.J.; Harding, C.M.; Amin, M.N.; Cross, A.S.; LaRocque, R.C.; Rosen, D.A.; Harris, J.B. Antibody responses in Klebsiella pneumoniae bloodstream infection: a prospective cohort study. Lancet Microbe 2025, DOI: 10.1016/j.lanmic.2024.100988. Wantuch, P.L.; Knoot, C.J.; Marino,
- [Blog](https://omniose.com/blog/) - Blog
- [Footer](https://omniose.com/home/footer/) - info@omniose.com © 2024 Omniose. All rights reserved
- [Contact](https://omniose.com/contact/) - For inquiries about Omniose, please contact us at: Location4340 Duncan Avenue, Suite 202 St. Louis, MO 63110 Email Usinfo@omniose.com
- [Accordions & Tabs](https://omniose.com/accordions-tabs/) - Outline accordion Leverage agile frameworks to provide a robust synopsis for high level overviews. Iterative approaches to corporate strategy foster collaborative thinking to further the overall value proposition. Organically grow the holistic world view of disruptive innovation via workplace diversity and empowerment. Accent font, light background Bring to the table win-win survival strategies to ensure
- [Social Media](https://omniose.com/social-media/) - Twitter[bt_bb_twitter gap="small" cache_id="5ba25978e00a2" number="2" display_type="regular" show_avatar="no" slides_to_show="" auto_play="" username="bold_themes" cache="5" consumer_key="3RKw3mkdTq49kYZRPiRkKbwap" consumer_secret="I0tQkQmaGoGcIa9IWYojVXMNXHaUiSvIjY5lXSgdrQ39w3WX4D" access_token="785807466890088448-jKVWn0m7JVkpPv1qW7vSfbPqRgUm4zZ" access_token_secret="L7lR9UBIouutb5osZeEOUrbp4vNj0JCGuZAcY5ZUVjRC8" responsive="" publish_datetime="" expiry_datetime="" el_id="" el_class="" el_style=""][/bt_bb_twitter]
- [Our History](https://omniose.com/technology/history/) - 2018MARCH 2018Molecular Diagnostics UpgradeCollaboratively administrate empowered markets via plug-and-play networks. Dynamically procrastinate B2C users after installed base benefits. Efficiently unleash cross-media without cross-media value. Quickly maximize timely deliverables for real-time schemas. Dramatically maintain clicks-and-mortar solutions without functional solutions.[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]2019FEBRUARY 2019Clinical Efficacy TestingCapitalize on low hanging fruit to identify a
- [Blog Single - Column, No sidebar](https://omniose.com/news/blog-single-column-no-sidebar/)
- [Blog Layouts](https://omniose.com/blog-layouts/) - OUR NEWSMasonry Post GridAllPress ReleaseOUR NEWSLatest Posts27 September 2023Omniose Awarded NIH Grant of up to $3.0 Million to Develop Vaccines against Group B Streptococcus
- [Buttons](https://omniose.com/buttons/) - Filled & SmallFilled & MediumFilled & NormalFilled & LargeRounded & SmallRounded & MediumRounded & NormalRounded & LargeRound & OutlineRound & OutlineRound & OutlineRound & OutlineUnderline & SmallUnderline & MediumUnderline & NormalUnderline & LargeBOOK APPOINTMENTBOOK APPOINTMENTBOOK APPOINTMENTClean & Accent ColorClean & Accent ColorClean & Accent ColorClean & Accent Color
- [Blog Single](https://omniose.com/news/blog-single/)

## Portfolio

- [A Case of Chronic Thrombocytopenia in a 17-Year-Old](https://omniose.com/case-studies/a-case-of-cronic-thrombocytopenia-in-a-17-year-old/) - Organically grow the holistic world view of disruptive innovation via workplace diversity and empowerment. User generated content in real-time.
- [Cryoglobulinemia as a Possible Primer for TRALI: Report](https://omniose.com/case-studies/cryoglobulinemia-as-a-possible-primer-for-trali/) - Frameworks to provide a robust synopsis for high level overviews. Iterative approaches to corporate strategy foster collaborative thinking.
- [Monitoring Fondaparinux in the Setting of Lab Antithrombin](https://omniose.com/case-studies/monitoring-fondaparinux-in-the-setting-of-lab-antithrombin/) - Efficiently unleash cross-media information without cross-media value. Quickly maximize timely deliverables for real-time schemas.
- [Establishing the Cause of Anemia in a Premature Newborn Infant](https://omniose.com/case-studies/establishing-the-cause-of-anemia-in-a-premature-newborn-infant/) - New normal that has evolved from generation X is on the runway heading towards a streamlined cloud solution. Capitalise on low hanging fruit.
- [R634W KIT Mutation in an Adult With Systemic Mastocytosis](https://omniose.com/case-studies/r634w-kit-mutation-in-an-adult-with-systemic-mastocytosis/) - Committed to delivering high quality projects and innovate business solutions. Bring to the table win-win survival strategies to ensure proactive domination.

## Categories

- [Press Release](https://omniose.com/category/press-release/)

## Portfolio Categories

- [Chemistry](https://omniose.com/case-studies-category/chemistry/)
- [Equipment](https://omniose.com/case-studies-category/equipment/)
- [Gemological](https://omniose.com/case-studies-category/gemological/)
- [Laboratory](https://omniose.com/case-studies-category/laboratory/)
- [Medical](https://omniose.com/case-studies-category/medical/)
- [Scientific](https://omniose.com/case-studies-category/scientific/)